How would you manage multiple myeloma with a suboptimal response to frontline quadruplet therapy?
When would you consider utilizing autologous SCT in those with a PR or SD?
Is there a potential role for BCMA-directed CAR-T or bispecific therapy in these patients? Are there current clinical trials evaluating this population with these therapies?
Answer from: Medical Oncologist at Community Practice
A suboptimal response, i.e. less than PR, to 4-drug induction is likely a poor prognostic sign, I just don't know how poor. This does not mean that you should follow induction with a tandem autologous transplant, CART, or bispecific as we don't know whether it's better than just moving forward with ...
Sign in or Register to read more